Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].

Autor: Melikyan AL; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Subortseva IN; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Sudarikov AB; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Kovrigina AM; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Gilyazitdinova EA; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Kolosheinova TI; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Abdullaev AO; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia., Treglazova SA; National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2017; Vol. 89 (7), pp. 4-9.

Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.

Autor: Tutaeva V; National Hematology Research Centre, Moscow, Russia., Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND

Publikováno v: Hematology (Amsterdam, Netherlands) [Hematology] 2007 Dec; Vol. 12 (6), pp. 473-9.